Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial
Background CheckMate 025 has shown superior efficacy for nivolumab over everolimus in patients with advanced renal cell carcinoma (aRCC) along with improved safety and tolerability. This analysis assesses the long‐term clinical benefits of nivolumab versus everolimus. Methods The randomized, open‐la...
Saved in:
| Published in: | Cancer Vol. 126; no. 18; pp. 4156 - 4167 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
United States
Wiley Subscription Services, Inc
15.09.2020
|
| Subjects: | |
| ISSN: | 0008-543X, 1097-0142, 1097-0142 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Background
CheckMate 025 has shown superior efficacy for nivolumab over everolimus in patients with advanced renal cell carcinoma (aRCC) along with improved safety and tolerability. This analysis assesses the long‐term clinical benefits of nivolumab versus everolimus.
Methods
The randomized, open‐label, phase 3 CheckMate 025 trial (NCT01668784) included patients with clear cell aRCC previously treated with 1 or 2 antiangiogenic regimens. Patients were randomized to nivolumab (3 mg/kg every 2 weeks) or everolimus (10 mg once a day) until progression or unacceptable toxicity. The primary endpoint was overall survival (OS). The secondary endpoints were the confirmed objective response rate (ORR), progression‐free survival (PFS), safety, and health‐related quality of life (HRQOL).
Results
Eight hundred twenty‐one patients were randomized to nivolumab (n = 410) or everolimus (n = 411); 803 patients were treated (406 with nivolumab and 397 with everolimus). With a minimum follow‐up of 64 months (median, 72 months), nivolumab maintained an OS benefit in comparison with everolimus (median, 25.8 months [95% CI, 22.2‐29.8 months] vs 19.7 months [95% CI, 17.6‐22.1 months]; hazard ratio [HR], 0.73; 95% CI, 0.62‐0.85) with 5‐year OS probabilities of 26% and 18%, respectively. ORR was higher with nivolumab (94 of 410 [23%] vs 17 of 411 [4%]; P < .001). PFS also favored nivolumab (HR, 0.84; 95% CI, 0.72‐0.99; P = .0331). The most common treatment‐related adverse events of any grade were fatigue (34.7%) and pruritus (15.5%) with nivolumab and fatigue (34.5%) and stomatitis (29.5%) with everolimus. HRQOL improved from baseline with nivolumab but remained the same or deteriorated with everolimus.
Conclusions
The superior efficacy of nivolumab over everolimus is maintained after extended follow‐up with no new safety signals, and this supports the long‐term benefits of nivolumab monotherapy in patients with previously treated aRCC.
LAY SUMMARY
CheckMate 025 compared the effects of nivolumab (a novel immunotherapy) with those of everolimus (an older standard‐of‐care therapy) for the treatment of advanced kidney cancer in patients who had progressed on antiangiogenic therapy.
After 5 years of study, nivolumab continues to be better than everolimus in extending the lives of patients, providing a long‐lasting response to treatment, and improving quality of life with a manageable safety profile. The results demonstrate that the clinical benefits of nivolumab versus everolimus in previously treated patients with advanced kidney cancer continue in the long term.
The results of the 5‐year follow‐up analysis of the CheckMate 025 trial demonstrate that the clinical benefits are sustained with nivolumab over everolimus in previously treated patients with advanced renal cell carcinoma in the long term. Overall survival, progression‐free survival, and objective response rate benefits are maintained with nivolumab versus everolimus, and more patients treated with nivolumab experience improved health‐related quality of life; meanwhile, the safety of nivolumab is manageable and compares favorably with that of everolimus. |
|---|---|
| AbstractList | CheckMate 025 has shown superior efficacy for nivolumab over everolimus in patients with advanced renal cell carcinoma (aRCC) along with improved safety and tolerability. This analysis assesses the long-term clinical benefits of nivolumab versus everolimus.
The randomized, open-label, phase 3 CheckMate 025 trial (NCT01668784) included patients with clear cell aRCC previously treated with 1 or 2 antiangiogenic regimens. Patients were randomized to nivolumab (3 mg/kg every 2 weeks) or everolimus (10 mg once a day) until progression or unacceptable toxicity. The primary endpoint was overall survival (OS). The secondary endpoints were the confirmed objective response rate (ORR), progression-free survival (PFS), safety, and health-related quality of life (HRQOL).
Eight hundred twenty-one patients were randomized to nivolumab (n = 410) or everolimus (n = 411); 803 patients were treated (406 with nivolumab and 397 with everolimus). With a minimum follow-up of 64 months (median, 72 months), nivolumab maintained an OS benefit in comparison with everolimus (median, 25.8 months [95% CI, 22.2-29.8 months] vs 19.7 months [95% CI, 17.6-22.1 months]; hazard ratio [HR], 0.73; 95% CI, 0.62-0.85) with 5-year OS probabilities of 26% and 18%, respectively. ORR was higher with nivolumab (94 of 410 [23%] vs 17 of 411 [4%]; P < .001). PFS also favored nivolumab (HR, 0.84; 95% CI, 0.72-0.99; P = .0331). The most common treatment-related adverse events of any grade were fatigue (34.7%) and pruritus (15.5%) with nivolumab and fatigue (34.5%) and stomatitis (29.5%) with everolimus. HRQOL improved from baseline with nivolumab but remained the same or deteriorated with everolimus.
The superior efficacy of nivolumab over everolimus is maintained after extended follow-up with no new safety signals, and this supports the long-term benefits of nivolumab monotherapy in patients with previously treated aRCC.
CheckMate 025 compared the effects of nivolumab (a novel immunotherapy) with those of everolimus (an older standard-of-care therapy) for the treatment of advanced kidney cancer in patients who had progressed on antiangiogenic therapy. After 5 years of study, nivolumab continues to be better than everolimus in extending the lives of patients, providing a long-lasting response to treatment, and improving quality of life with a manageable safety profile. The results demonstrate that the clinical benefits of nivolumab versus everolimus in previously treated patients with advanced kidney cancer continue in the long term. CheckMate 025 compared the effects of nivolumab (a novel immunotherapy) with everolimus (an older standard-of-care therapy) for the treatment of advanced kidney cancer in patients who had progressed on antiangiogenic therapy. After 5 years of study, nivolumab continues to be better than everolimus in extending the lives of patients, providing a long-lasting response to treatment and improving quality of life with a manageable safety profile. The results demonstrate that the clinical benefits with nivolumab compared with everolimus in previously treated patients with advanced kidney cancer continue in the long term. The results of the 5-year follow-up analysis of the CheckMate 025 trial demonstrate that the clinical benefits are sustained with nivolumab over everolimus in previously treated patients with aRCC in the long term. OS, PFS, and ORR benefits are maintained with nivolumab versus everolimus, and more patients treated with nivolumab experience an improved HRQoL, while the safety of nivolumab is manageable and compares favorably with everolimus. CheckMate 025 has shown superior efficacy for nivolumab over everolimus in patients with advanced renal cell carcinoma (aRCC) along with improved safety and tolerability. This analysis assesses the long-term clinical benefits of nivolumab versus everolimus.BACKGROUNDCheckMate 025 has shown superior efficacy for nivolumab over everolimus in patients with advanced renal cell carcinoma (aRCC) along with improved safety and tolerability. This analysis assesses the long-term clinical benefits of nivolumab versus everolimus.The randomized, open-label, phase 3 CheckMate 025 trial (NCT01668784) included patients with clear cell aRCC previously treated with 1 or 2 antiangiogenic regimens. Patients were randomized to nivolumab (3 mg/kg every 2 weeks) or everolimus (10 mg once a day) until progression or unacceptable toxicity. The primary endpoint was overall survival (OS). The secondary endpoints were the confirmed objective response rate (ORR), progression-free survival (PFS), safety, and health-related quality of life (HRQOL).METHODSThe randomized, open-label, phase 3 CheckMate 025 trial (NCT01668784) included patients with clear cell aRCC previously treated with 1 or 2 antiangiogenic regimens. Patients were randomized to nivolumab (3 mg/kg every 2 weeks) or everolimus (10 mg once a day) until progression or unacceptable toxicity. The primary endpoint was overall survival (OS). The secondary endpoints were the confirmed objective response rate (ORR), progression-free survival (PFS), safety, and health-related quality of life (HRQOL).Eight hundred twenty-one patients were randomized to nivolumab (n = 410) or everolimus (n = 411); 803 patients were treated (406 with nivolumab and 397 with everolimus). With a minimum follow-up of 64 months (median, 72 months), nivolumab maintained an OS benefit in comparison with everolimus (median, 25.8 months [95% CI, 22.2-29.8 months] vs 19.7 months [95% CI, 17.6-22.1 months]; hazard ratio [HR], 0.73; 95% CI, 0.62-0.85) with 5-year OS probabilities of 26% and 18%, respectively. ORR was higher with nivolumab (94 of 410 [23%] vs 17 of 411 [4%]; P < .001). PFS also favored nivolumab (HR, 0.84; 95% CI, 0.72-0.99; P = .0331). The most common treatment-related adverse events of any grade were fatigue (34.7%) and pruritus (15.5%) with nivolumab and fatigue (34.5%) and stomatitis (29.5%) with everolimus. HRQOL improved from baseline with nivolumab but remained the same or deteriorated with everolimus.RESULTSEight hundred twenty-one patients were randomized to nivolumab (n = 410) or everolimus (n = 411); 803 patients were treated (406 with nivolumab and 397 with everolimus). With a minimum follow-up of 64 months (median, 72 months), nivolumab maintained an OS benefit in comparison with everolimus (median, 25.8 months [95% CI, 22.2-29.8 months] vs 19.7 months [95% CI, 17.6-22.1 months]; hazard ratio [HR], 0.73; 95% CI, 0.62-0.85) with 5-year OS probabilities of 26% and 18%, respectively. ORR was higher with nivolumab (94 of 410 [23%] vs 17 of 411 [4%]; P < .001). PFS also favored nivolumab (HR, 0.84; 95% CI, 0.72-0.99; P = .0331). The most common treatment-related adverse events of any grade were fatigue (34.7%) and pruritus (15.5%) with nivolumab and fatigue (34.5%) and stomatitis (29.5%) with everolimus. HRQOL improved from baseline with nivolumab but remained the same or deteriorated with everolimus.The superior efficacy of nivolumab over everolimus is maintained after extended follow-up with no new safety signals, and this supports the long-term benefits of nivolumab monotherapy in patients with previously treated aRCC.CONCLUSIONSThe superior efficacy of nivolumab over everolimus is maintained after extended follow-up with no new safety signals, and this supports the long-term benefits of nivolumab monotherapy in patients with previously treated aRCC.CheckMate 025 compared the effects of nivolumab (a novel immunotherapy) with those of everolimus (an older standard-of-care therapy) for the treatment of advanced kidney cancer in patients who had progressed on antiangiogenic therapy. After 5 years of study, nivolumab continues to be better than everolimus in extending the lives of patients, providing a long-lasting response to treatment, and improving quality of life with a manageable safety profile. The results demonstrate that the clinical benefits of nivolumab versus everolimus in previously treated patients with advanced kidney cancer continue in the long term.LAY SUMMARYCheckMate 025 compared the effects of nivolumab (a novel immunotherapy) with those of everolimus (an older standard-of-care therapy) for the treatment of advanced kidney cancer in patients who had progressed on antiangiogenic therapy. After 5 years of study, nivolumab continues to be better than everolimus in extending the lives of patients, providing a long-lasting response to treatment, and improving quality of life with a manageable safety profile. The results demonstrate that the clinical benefits of nivolumab versus everolimus in previously treated patients with advanced kidney cancer continue in the long term. Background CheckMate 025 has shown superior efficacy for nivolumab over everolimus in patients with advanced renal cell carcinoma (aRCC) along with improved safety and tolerability. This analysis assesses the long‐term clinical benefits of nivolumab versus everolimus. Methods The randomized, open‐label, phase 3 CheckMate 025 trial (NCT01668784) included patients with clear cell aRCC previously treated with 1 or 2 antiangiogenic regimens. Patients were randomized to nivolumab (3 mg/kg every 2 weeks) or everolimus (10 mg once a day) until progression or unacceptable toxicity. The primary endpoint was overall survival (OS). The secondary endpoints were the confirmed objective response rate (ORR), progression‐free survival (PFS), safety, and health‐related quality of life (HRQOL). Results Eight hundred twenty‐one patients were randomized to nivolumab (n = 410) or everolimus (n = 411); 803 patients were treated (406 with nivolumab and 397 with everolimus). With a minimum follow‐up of 64 months (median, 72 months), nivolumab maintained an OS benefit in comparison with everolimus (median, 25.8 months [95% CI, 22.2‐29.8 months] vs 19.7 months [95% CI, 17.6‐22.1 months]; hazard ratio [HR], 0.73; 95% CI, 0.62‐0.85) with 5‐year OS probabilities of 26% and 18%, respectively. ORR was higher with nivolumab (94 of 410 [23%] vs 17 of 411 [4%]; P < .001). PFS also favored nivolumab (HR, 0.84; 95% CI, 0.72‐0.99; P = .0331). The most common treatment‐related adverse events of any grade were fatigue (34.7%) and pruritus (15.5%) with nivolumab and fatigue (34.5%) and stomatitis (29.5%) with everolimus. HRQOL improved from baseline with nivolumab but remained the same or deteriorated with everolimus. Conclusions The superior efficacy of nivolumab over everolimus is maintained after extended follow‐up with no new safety signals, and this supports the long‐term benefits of nivolumab monotherapy in patients with previously treated aRCC. LAY SUMMARY CheckMate 025 compared the effects of nivolumab (a novel immunotherapy) with those of everolimus (an older standard‐of‐care therapy) for the treatment of advanced kidney cancer in patients who had progressed on antiangiogenic therapy. After 5 years of study, nivolumab continues to be better than everolimus in extending the lives of patients, providing a long‐lasting response to treatment, and improving quality of life with a manageable safety profile. The results demonstrate that the clinical benefits of nivolumab versus everolimus in previously treated patients with advanced kidney cancer continue in the long term. The results of the 5‐year follow‐up analysis of the CheckMate 025 trial demonstrate that the clinical benefits are sustained with nivolumab over everolimus in previously treated patients with advanced renal cell carcinoma in the long term. Overall survival, progression‐free survival, and objective response rate benefits are maintained with nivolumab versus everolimus, and more patients treated with nivolumab experience improved health‐related quality of life; meanwhile, the safety of nivolumab is manageable and compares favorably with that of everolimus. The results of the 5‐year follow‐up analysis of the CheckMate 025 trial demonstrate that the clinical benefits are sustained with nivolumab over everolimus in previously treated patients with advanced renal cell carcinoma in the long term. Overall survival, progression‐free survival, and objective response rate benefits are maintained with nivolumab versus everolimus, and more patients treated with nivolumab experience improved health‐related quality of life; meanwhile, the safety of nivolumab is manageable and compares favorably with that of everolimus. BackgroundCheckMate 025 has shown superior efficacy for nivolumab over everolimus in patients with advanced renal cell carcinoma (aRCC) along with improved safety and tolerability. This analysis assesses the long‐term clinical benefits of nivolumab versus everolimus.MethodsThe randomized, open‐label, phase 3 CheckMate 025 trial (NCT01668784) included patients with clear cell aRCC previously treated with 1 or 2 antiangiogenic regimens. Patients were randomized to nivolumab (3 mg/kg every 2 weeks) or everolimus (10 mg once a day) until progression or unacceptable toxicity. The primary endpoint was overall survival (OS). The secondary endpoints were the confirmed objective response rate (ORR), progression‐free survival (PFS), safety, and health‐related quality of life (HRQOL).ResultsEight hundred twenty‐one patients were randomized to nivolumab (n = 410) or everolimus (n = 411); 803 patients were treated (406 with nivolumab and 397 with everolimus). With a minimum follow‐up of 64 months (median, 72 months), nivolumab maintained an OS benefit in comparison with everolimus (median, 25.8 months [95% CI, 22.2‐29.8 months] vs 19.7 months [95% CI, 17.6‐22.1 months]; hazard ratio [HR], 0.73; 95% CI, 0.62‐0.85) with 5‐year OS probabilities of 26% and 18%, respectively. ORR was higher with nivolumab (94 of 410 [23%] vs 17 of 411 [4%]; P < .001). PFS also favored nivolumab (HR, 0.84; 95% CI, 0.72‐0.99; P = .0331). The most common treatment‐related adverse events of any grade were fatigue (34.7%) and pruritus (15.5%) with nivolumab and fatigue (34.5%) and stomatitis (29.5%) with everolimus. HRQOL improved from baseline with nivolumab but remained the same or deteriorated with everolimus.ConclusionsThe superior efficacy of nivolumab over everolimus is maintained after extended follow‐up with no new safety signals, and this supports the long‐term benefits of nivolumab monotherapy in patients with previously treated aRCC.LAY SUMMARYCheckMate 025 compared the effects of nivolumab (a novel immunotherapy) with those of everolimus (an older standard‐of‐care therapy) for the treatment of advanced kidney cancer in patients who had progressed on antiangiogenic therapy.After 5 years of study, nivolumab continues to be better than everolimus in extending the lives of patients, providing a long‐lasting response to treatment, and improving quality of life with a manageable safety profile. The results demonstrate that the clinical benefits of nivolumab versus everolimus in previously treated patients with advanced kidney cancer continue in the long term. |
| Author | Sosman, Jeffrey A. Saggi, Shruti Shally Hammers, Hans J. Peltola, Katriina George, Saby Castellano, Daniel Gauler, Thomas C. Choueiri, Toni K. Alva, Ajjai S. Donskov, Frede Gurney, Howard Motzer, Robert J. Srinivas, Sandhya Larkin, James Plimack, Elizabeth R. Tomita, Yoshihiko Carducci, Michael Cella, David McHenry, M. Brent Procopio, Giuseppe Tannir, Nizar M. Richardet, Martin Fukasawa, Satoshi McDermott, David F. Chevreau, Christine Kollmannsberger, Christian K. Escudier, Bernard Schutz, Fabio A. Oudard, Stéphane Wagstaff, John Tykodi, Scott S. |
| AuthorAffiliation | 2 Department of Medical Oncology, Gustave Roussy, Villejuif, France 24 Department of Medicine, University Hospital Essen of University of Duisburg-Essen, Germany 6 Department of Medicine, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, Washington 11 Oncologia Medica, Hospital Universitario 12 De Octubre, Madrid, Spain 5 Stanford Cancer Institute, Stanford University Medical Center, Stanford, California 3 Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York 18 Division of Hematology and Oncology, University of Michigan, Ann Arbor, Michigan 19 Johns Hopkins Medicine, Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland 9 Fondazione Istituto Nazionale Tumori, Milan, Italy 17 Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland 8 Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 10 Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center, Boston, Massachusetts 16 Fund |
| AuthorAffiliation_xml | – name: 20 South West Wales Cancer Institute and Swansea University College of Medicine, Swansea, UK – name: 18 Division of Hematology and Oncology, University of Michigan, Ann Arbor, Michigan – name: 19 Johns Hopkins Medicine, Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland – name: 26 Beneficencia Portuguesa de São Paulo, São Paulo, Brazil – name: 21 IUCT-O Institut Claudius Regaud, Toulouse, France – name: 13 Department of Oncology, Aarhus University Hospital, Aarhus, Denmark (Prof F Donskov MD) – name: 7 Departments of Hematology Oncology Northwestern University Medical Center, Chicago, Illinois – name: 30 Department of Clinical Trials, Bristol Myers Squibb, Princeton, New Jersey – name: 5 Stanford Cancer Institute, Stanford University Medical Center, Stanford, California – name: 10 Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center, Boston, Massachusetts – name: 4 Division of Hematology and Oncology, UT Southwestern Kidney Cancer Program, Dallas, Texas – name: 25 Division of Medical Oncology, BC Cancer - Vancouver Cancer Centre, Vancouver, British Columbia, Canada – name: 2 Department of Medical Oncology, Gustave Roussy, Villejuif, France – name: 22 Prostate Center and Division of Urology, Chiba Cancer Center, Chiba, Japan – name: 28 Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Feinberg School of Medicine, Chicago, Illinois – name: 8 Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania – name: 14 Department of Medical Oncology, Westmead Hospital and Macquarie University, Westmead, New South Wales, Australia – name: 29 Department of Biostatistics, Bristol Myers Squibb, Princeton, New Jersey – name: 3 Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York – name: 24 Department of Medicine, University Hospital Essen of University of Duisburg-Essen, Germany – name: 1 Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York – name: 15 Service de Cancérologie Médicale, Hôpital Européen Georges Pompidou, AP-HP, Paris, France – name: 9 Fondazione Istituto Nazionale Tumori, Milan, Italy – name: 31 Department of Genitourinary Medical Oncology, MD Anderson Cancer Center, University of Texas, Houston, Texas – name: 16 Fundacion Richardet Longo, Instituto Oncologico de Cordoba, Cordoba, Argentina – name: 27 Royal Marsden Hospital NHS Foundation Trust, London, UK – name: 12 Dana-Farber Cancer Institute, The Lank Center for Genitourinary Oncology, Boston, Massachusetts – name: 11 Oncologia Medica, Hospital Universitario 12 De Octubre, Madrid, Spain – name: 6 Department of Medicine, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, Washington – name: 23 Department of Urology, Department of Molecular Oncology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan – name: 17 Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland |
| Author_xml | – sequence: 1 givenname: Robert J. orcidid: 0000-0001-6925-2327 surname: Motzer fullname: Motzer, Robert J. email: motzerr@mskcc.org organization: Memorial Sloan Kettering Cancer Center – sequence: 2 givenname: Bernard surname: Escudier fullname: Escudier, Bernard organization: Gustave Roussy – sequence: 3 givenname: Saby surname: George fullname: George, Saby organization: Roswell Park Cancer Institute – sequence: 4 givenname: Hans J. surname: Hammers fullname: Hammers, Hans J. – sequence: 5 givenname: Sandhya surname: Srinivas fullname: Srinivas, Sandhya organization: Stanford University Medical Center – sequence: 6 givenname: Scott S. surname: Tykodi fullname: Tykodi, Scott S. organization: University of Washington and Fred Hutchinson Cancer Research Center – sequence: 7 givenname: Jeffrey A. surname: Sosman fullname: Sosman, Jeffrey A. organization: Northwestern University Medical Center – sequence: 8 givenname: Elizabeth R. surname: Plimack fullname: Plimack, Elizabeth R. organization: Fox Chase Cancer Center – sequence: 9 givenname: Giuseppe orcidid: 0000-0002-2498-402X surname: Procopio fullname: Procopio, Giuseppe organization: Fondazione Istituto Nazionale Tumori – sequence: 10 givenname: David F. surname: McDermott fullname: McDermott, David F. organization: Beth Israel Deaconess Medical Center, Dana‐Farber/Harvard Cancer Center – sequence: 11 givenname: Daniel surname: Castellano fullname: Castellano, Daniel organization: Hospital Universitario 12 De Octubre – sequence: 12 givenname: Toni K. orcidid: 0000-0002-9201-3217 surname: Choueiri fullname: Choueiri, Toni K. organization: Dana‐Farber Cancer Institute – sequence: 13 givenname: Frede surname: Donskov fullname: Donskov, Frede organization: Aarhus University Hospital – sequence: 14 givenname: Howard surname: Gurney fullname: Gurney, Howard organization: Westmead Hospital and Macquarie University – sequence: 15 givenname: Stéphane surname: Oudard fullname: Oudard, Stéphane organization: Hôpital Européen Georges Pompidou, Assistance Publique–Hôpitaux de Paris – sequence: 16 givenname: Martin surname: Richardet fullname: Richardet, Martin organization: Instituto Oncologico de Cordoba – sequence: 17 givenname: Katriina surname: Peltola fullname: Peltola, Katriina organization: Helsinki University Hospital – sequence: 18 givenname: Ajjai S. surname: Alva fullname: Alva, Ajjai S. organization: University of Michigan – sequence: 19 givenname: Michael surname: Carducci fullname: Carducci, Michael organization: Johns Hopkins Medicine – sequence: 20 givenname: John orcidid: 0000-0002-1140-5981 surname: Wagstaff fullname: Wagstaff, John organization: South West Wales Cancer Institute and Swansea University College of Medicine – sequence: 21 givenname: Christine orcidid: 0000-0001-9866-913X surname: Chevreau fullname: Chevreau, Christine organization: Institut Universitaire du Cancer de Toulouse ‐ Oncopole – sequence: 22 givenname: Satoshi surname: Fukasawa fullname: Fukasawa, Satoshi organization: Chiba Cancer Center – sequence: 23 givenname: Yoshihiko surname: Tomita fullname: Tomita, Yoshihiko organization: Niigata University Graduate School of Medical and Dental Sciences – sequence: 24 givenname: Thomas C. surname: Gauler fullname: Gauler, Thomas C. organization: University Hospital Essen, University of Duisburg‐Essen – sequence: 25 givenname: Christian K. surname: Kollmannsberger fullname: Kollmannsberger, Christian K. organization: BC Cancer–Vancouver Cancer Centre – sequence: 26 givenname: Fabio A. surname: Schutz fullname: Schutz, Fabio A. organization: Beneficencia Portuguesa de São Paulo – sequence: 27 givenname: James surname: Larkin fullname: Larkin, James organization: Royal Marsden Hospital NHS Foundation Trust – sequence: 28 givenname: David surname: Cella fullname: Cella, David organization: Northwestern University – sequence: 29 givenname: M. Brent surname: McHenry fullname: McHenry, M. Brent organization: Bristol Myers Squibb – sequence: 30 givenname: Shruti Shally surname: Saggi fullname: Saggi, Shruti Shally organization: Bristol Myers Squibb – sequence: 31 givenname: Nizar M. surname: Tannir fullname: Tannir, Nizar M. organization: The University of Texas MD Anderson Cancer Center |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32673417$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kt1qVDEQx4NUbLt64wNIwBuRbs3X-eqFIItfUCuIBe9CTjKnm5qTHJNzdqlXPoIv4wv5JGa7XdEi3iQZ5vf_Z5iZQ7TngweEHlJyTAlhz7TX8ZhzwvkddEBJU80JFWwPHRBC6nkh-Kd9dJjSZQ4rVvB7aJ-zsuKCVgfox5ldBTf1qsUriGlKGPIdnO3z03o8qNGCHxNe23GJlVkpr8HgCF45rMHlQ0VtfejVCT4fjBqvs2lyO40L_uLnt-8jxB53wbmwztE04NDhcQk4Km9Cb7-COcJhAJ-TTrXgjvCwVAkwx4sl6M_vsjEmrMBjtMrdR3c75RI8uLln6PzVy4-LN_PT96_fLl6czrUQNZ8rUpVGaNOUTck5143QpKWaCN7QrmxNoVttco8og7JkZV3Xla4aowpdQUuLjs_Q863vMLU9GJ07EZWTQ7S9ilcyKCv_zni7lBdhJWtBC5I_naEnNwYxfJkgjbK3adM25SFMSTLBijzCirGMPr6FXoYp5jZvKF7WDWWlyNSjPyv6XcpuohkgW0DHkFKETmo75iGGTYHWSUrkZmnkZmnk9dJkydNbkp3rP2G6hdfWwdV_SLk4W3zYan4BUyHYDQ |
| CitedBy_id | crossref_primary_10_1016_j_intimp_2023_110982 crossref_primary_10_1186_s12885_024_12319_1 crossref_primary_10_3390_cancers13215415 crossref_primary_10_3390_cancers15041316 crossref_primary_10_1038_s41591_024_02978_9 crossref_primary_10_3389_fimmu_2023_1276658 crossref_primary_10_3233_KCA_230013 crossref_primary_10_36290_uro_2024_015 crossref_primary_10_1186_s12894_023_01248_z crossref_primary_10_1186_s12967_021_02784_8 crossref_primary_10_3390_cancers15123172 crossref_primary_10_1007_s11523_022_00892_z crossref_primary_10_1016_j_ejmech_2024_116158 crossref_primary_10_3390_cells13010034 crossref_primary_10_3390_cancers13205065 crossref_primary_10_1007_s11560_024_00769_4 crossref_primary_10_1097_MD_0000000000029510 crossref_primary_10_1177_17588359211019642 crossref_primary_10_1007_s00432_022_04173_0 crossref_primary_10_1016_j_intimp_2025_115527 crossref_primary_10_1007_s00296_022_05247_5 crossref_primary_10_1007_s12325_023_02513_1 crossref_primary_10_3233_KCA_230007 crossref_primary_10_1016_S1470_2045_23_00449_7 crossref_primary_10_1186_s12967_024_05015_y crossref_primary_10_7554_eLife_89017 crossref_primary_10_1080_14737140_2022_2072300 crossref_primary_10_3390_cancers17091434 crossref_primary_10_2147_CMAR_S267220 crossref_primary_10_1111_sji_13197 crossref_primary_10_2174_0113816128262498231122072050 crossref_primary_10_1016_j_ucl_2023_01_012 crossref_primary_10_3389_fimmu_2021_701951 crossref_primary_10_3389_fimmu_2023_1146738 crossref_primary_10_1007_s10143_022_01839_8 crossref_primary_10_1016_j_critrevonc_2022_103881 crossref_primary_10_1055_a_1579_0562 crossref_primary_10_3390_life11111277 crossref_primary_10_3390_jpm12060862 crossref_primary_10_2217_imt_2021_0207 crossref_primary_10_1016_j_ccell_2022_08_005 crossref_primary_10_1093_jjco_hyac044 crossref_primary_10_3390_ijms26125577 crossref_primary_10_1007_s10147_025_02715_3 crossref_primary_10_4274_jus_galenos_2025_2024_11_9 crossref_primary_10_1186_s12885_024_12998_w crossref_primary_10_1016_j_clgc_2023_11_012 crossref_primary_10_1186_s12967_024_05426_x crossref_primary_10_1016_j_path_2024_10_002 crossref_primary_10_1158_1078_0432_CCR_22_0630 crossref_primary_10_3389_fonc_2021_746976 crossref_primary_10_1080_17843286_2021_1903662 crossref_primary_10_1080_13543784_2021_2014814 crossref_primary_10_3389_fonc_2021_706910 crossref_primary_10_1007_s10238_024_01541_7 crossref_primary_10_3390_jcm13020307 crossref_primary_10_1016_j_ibmed_2025_100293 crossref_primary_10_1002_mco2_676 crossref_primary_10_1016_j_intimp_2023_110528 crossref_primary_10_3233_KCA_229003 crossref_primary_10_3390_jcm12123888 crossref_primary_10_1007_s11523_023_01013_0 crossref_primary_10_1080_1750743X_2025_2527019 crossref_primary_10_7554_eLife_89017_3 crossref_primary_10_3390_cancers14102460 crossref_primary_10_3389_fnut_2022_810472 crossref_primary_10_1177_0272989X221132257 crossref_primary_10_1016_S0140_6736_24_00917_6 crossref_primary_10_1016_j_intimp_2022_108900 crossref_primary_10_1186_s12885_023_11702_8 crossref_primary_10_1017_S0266462322000125 crossref_primary_10_1177_17588359251317846 crossref_primary_10_1136_jitc_2024_010777 crossref_primary_10_1186_s12885_022_09694_y crossref_primary_10_3389_fimmu_2023_1321616 crossref_primary_10_1186_s12935_023_03183_3 crossref_primary_10_1002_cam4_5468 crossref_primary_10_3390_cancers14246207 crossref_primary_10_3390_cancers16020340 crossref_primary_10_1038_s41416_023_02464_y crossref_primary_10_1007_s00432_024_05663_z crossref_primary_10_1002_cam4_6671 crossref_primary_10_1038_s41573_023_00848_6 crossref_primary_10_2217_fon_2021_0717 crossref_primary_10_1155_2022_5430525 crossref_primary_10_3390_cancers14246230 crossref_primary_10_1038_s43018_025_00942_1 crossref_primary_10_1080_1750743X_2024_2385881 crossref_primary_10_3233_KCA_200108 crossref_primary_10_3390_life12030360 crossref_primary_10_1136_jitc_2022_004780 crossref_primary_10_1186_s12890_024_02943_9 crossref_primary_10_1159_000523904 crossref_primary_10_1186_s12885_025_14661_4 crossref_primary_10_3390_cancers12102828 crossref_primary_10_3390_cancers12113285 crossref_primary_10_1016_j_annonc_2025_03_016 crossref_primary_10_1155_2022_5687238 crossref_primary_10_1016_j_annepidem_2023_01_003 crossref_primary_10_1038_s41419_024_06837_w crossref_primary_10_3389_fonc_2021_645245 crossref_primary_10_1126_scitranslmed_abm6420 crossref_primary_10_1186_s12935_022_02816_3 crossref_primary_10_3389_fcell_2022_892616 crossref_primary_10_3390_cancers16040709 crossref_primary_10_1016_j_clon_2022_11_012 crossref_primary_10_1038_s41392_023_01522_4 crossref_primary_10_2217_fon_2021_1267 crossref_primary_10_3389_fgene_2022_866819 crossref_primary_10_1073_pnas_2103240118 crossref_primary_10_1016_j_clgc_2024_102267 crossref_primary_10_1016_j_euf_2021_11_006 crossref_primary_10_1016_j_eururo_2023_09_004 crossref_primary_10_3389_fonc_2022_960751 crossref_primary_10_1007_s10147_023_02446_3 crossref_primary_10_1016_j_acra_2022_03_007 crossref_primary_10_1016_j_intimp_2024_111681 crossref_primary_10_1016_j_heliyon_2024_e29215 crossref_primary_10_3390_biomedicines12051111 crossref_primary_10_3389_fonc_2022_969569 crossref_primary_10_1002_ccr3_70418 crossref_primary_10_1111_iju_15206 crossref_primary_10_3389_fimmu_2024_1458209 crossref_primary_10_1016_j_urolonc_2023_12_002 crossref_primary_10_1002_cam4_4208 crossref_primary_10_1080_07853890_2025_2495762 crossref_primary_10_1136_jitc_2021_003473 crossref_primary_10_3389_fonc_2021_763468 crossref_primary_10_1002_iju5_12225 crossref_primary_10_1136_jitc_2021_004206 crossref_primary_10_3389_fimmu_2023_1199089 crossref_primary_10_1007_s40261_023_01285_4 crossref_primary_10_1056_NEJMoa2313906 crossref_primary_10_3390_cancers13225856 crossref_primary_10_3389_fimmu_2022_974087 crossref_primary_10_1016_j_sjbs_2022_01_017 crossref_primary_10_3390_jcm13216537 crossref_primary_10_1007_s11912_022_01269_1 crossref_primary_10_1038_s41575_022_00741_4 crossref_primary_10_5306_wjco_v13_i1_1 crossref_primary_10_1007_s13205_024_03967_y crossref_primary_10_1016_j_currproblcancer_2021_100760 crossref_primary_10_3390_cancers15092500 crossref_primary_10_1007_s11864_023_01107_x crossref_primary_10_1016_j_esmogo_2024_100115 crossref_primary_10_1016_j_ymeth_2022_07_004 crossref_primary_10_3389_fonc_2020_609235 crossref_primary_10_1155_2022_8100323 crossref_primary_10_3390_biom11121792 crossref_primary_10_1111_iju_15265 crossref_primary_10_1615_CritRevImmunol_2025057711 crossref_primary_10_1016_j_urolonc_2020_10_019 crossref_primary_10_1007_s10238_024_01370_8 crossref_primary_10_1016_j_critrevonc_2023_104016 crossref_primary_10_1016_j_ejphar_2024_177202 crossref_primary_10_3389_fimmu_2023_1297408 crossref_primary_10_1007_s12094_023_03276_5 crossref_primary_10_26442_18151434_2025_1_203025 crossref_primary_10_1007_s00432_021_03762_9 crossref_primary_10_1186_s12967_021_03008_9 crossref_primary_10_3389_fgene_2020_593039 crossref_primary_10_1136_jitc_2022_006361 crossref_primary_10_1016_j_soncn_2025_151903 crossref_primary_10_3389_fmolb_2022_928006 crossref_primary_10_1080_14737140_2021_1959319 crossref_primary_10_1186_s12885_023_11150_4 crossref_primary_10_1016_j_urolonc_2021_04_038 crossref_primary_10_1111_iju_15130 crossref_primary_10_1002_cam4_4475 crossref_primary_10_1002_iju5_12427 crossref_primary_10_1080_26895293_2025_2467662 crossref_primary_10_1016_j_annonc_2021_09_014 crossref_primary_10_1097_MD_0000000000028113 crossref_primary_10_3233_KCA_220012 crossref_primary_10_1016_j_heliyon_2023_e17224 crossref_primary_10_1016_j_metabol_2025_156304 crossref_primary_10_1016_j_urolonc_2021_04_043 crossref_primary_10_3389_fonc_2022_924072 crossref_primary_10_1097_CCO_0000000000000802 crossref_primary_10_3390_jpm12050727 crossref_primary_10_1016_j_urolonc_2023_05_002 crossref_primary_10_1016_j_ejca_2024_114002 crossref_primary_10_3390_cancers13143492 crossref_primary_10_1016_j_canlet_2021_04_001 crossref_primary_10_1002_cam4_5504 crossref_primary_10_3389_fimmu_2024_1361010 crossref_primary_10_3390_cancers13215465 crossref_primary_10_3389_fphar_2023_1093194 crossref_primary_10_1158_1078_0432_CCR_21_4115 crossref_primary_10_3390_biomedicines11041071 crossref_primary_10_3390_cancers15245873 crossref_primary_10_2147_OTT_S282763 crossref_primary_10_1016_j_jval_2024_02_008 crossref_primary_10_1136_jitc_2021_002447 crossref_primary_10_3748_wjg_v27_i41_7190 crossref_primary_10_3390_ijms23116198 crossref_primary_10_3892_mco_2022_2512 crossref_primary_10_1007_s10147_022_02215_8 crossref_primary_10_1056_NEJMoa2106391 crossref_primary_10_3389_fonc_2021_679177 crossref_primary_10_1007_s00330_022_08793_5 crossref_primary_10_1055_a_2114_5952 crossref_primary_10_1016_j_vetimm_2024_110741 crossref_primary_10_1002_cam4_4679 crossref_primary_10_1002_ijc_33556 crossref_primary_10_1093_bib_bbac034 crossref_primary_10_1136_jitc_2020_001622 crossref_primary_10_1186_s12885_025_14654_3 crossref_primary_10_1016_j_retram_2025_103494 crossref_primary_10_1007_s00120_022_01793_9 crossref_primary_10_3390_jcm12144641 crossref_primary_10_1002_cam4_70143 |
| Cites_doi | 10.1634/theoncologist.2017-0534 10.1093/biomet/26.4.404 10.1200/JCO.1995.13.3.688 10.1073/pnas.192461099 10.1111/j.1524-4733.2007.00183.x 10.1200/JCO.2014.59.0703 10.1158/1078-0432.CCR-15-2839 10.1200/JCO.2009.26.7609 10.1002/cncr.21979 10.1111/j.2517-6161.1972.tb00899.x 10.1016/S1470-2045(19)30413-9 10.1016/S1470-2045(16)30125-5 10.1200/JCO.2014.58.1041 10.1056/NEJMoa1510665 10.1634/theoncologist.2019-0372 |
| ContentType | Journal Article |
| Copyright | 2020 American Cancer Society 2020 American Cancer Society. |
| Copyright_xml | – notice: 2020 American Cancer Society – notice: 2020 American Cancer Society. |
| DBID | AAYXX CITATION NPM 7TO 7U7 C1K H94 K9. NAPCQ 7X8 5PM |
| DOI | 10.1002/cncr.33033 |
| DatabaseName | CrossRef PubMed Oncogenes and Growth Factors Abstracts Toxicology Abstracts Environmental Sciences and Pollution Management AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef PubMed AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium Oncogenes and Growth Factors Abstracts Toxicology Abstracts Environmental Sciences and Pollution Management MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic CrossRef AIDS and Cancer Research Abstracts |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1097-0142 |
| EndPage | 4167 |
| ExternalDocumentID | PMC8415096 32673417 10_1002_cncr_33033 CNCR33033 |
| Genre | article Research Support, Non-U.S. Gov't Journal Article |
| GrantInformation_xml | – fundername: National Institutes of Health funderid: P30 CA016672 – fundername: Bristol‐Myers Squibb and ONO Pharmaceutical Company Ltd – fundername: Bristol-Myers Squibb and ONO Pharmaceutical Company Ltd – fundername: NIH HHS grantid: P30 CA016672 |
| GroupedDBID | --- -~X .3N .GA 05W 0R~ 10A 1CY 1L6 1OC 29B 33P 3SF 3WU 4.4 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5VS 66C 6J9 6P2 6PF 702 7PT 8-0 8-1 8-3 8-4 8-5 85S 8UM 930 A01 A03 AAESR AAEVG AAHQN AAIPD AAMMB AAMNL AANLZ AAONW AARRQ AAWTL AAXRX AAYCA AAZKR ABCQN ABCUV ABEML ABHFT ABIJN ABIVO ABJNI ABLJU ABOCM ABPPZ ABPVW ABQWH ABXGK ACAHQ ACCZN ACFBH ACGFO ACGFS ACGOF ACMXC ACNCT ACPOU ACPRK ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN AEFGJ AEIGN AEIMD AENEX AEUYR AEYWJ AFBPY AFFPM AFGKR AFRAH AFWVQ AFZJQ AGHNM AGXDD AGYGG AHBTC AIACR AIAGR AIDQK AIDYY AITYG AIURR ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ATUGU AZBYB AZVAB BAFTC BAWUL BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM E3Z EBS EMOBN EX3 F00 F01 F04 F5P FD6 FUBAC G-S G.N GNP GODZA GX1 H.X HBH HGLYW HHY HHZ HZ~ IH2 IX1 J0M JPC KBYEO KQQ KZ1 L7B LATKE LAW LC2 LC3 LH4 LITHE LMP LOXES LP6 LP7 LSO LUTES LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ NNB O66 O9- OIG OK1 OVD P2P P2W P2X P2Z P4B P4D Q.N Q11 QB0 QRW R.K ROL RX1 RYL SJN SUPJJ TEORI UDS UHB V2E V8K V9Y W8V W99 WBKPD WH7 WHWMO WIH WIJ WIK WIN WJL WOHZO WQJ WVDHM WXI WXSBR XG1 XPP XV2 Z0Y ZGI ZZTAW ~IA ~WT AAYXX CITATION O8X AAHHS ADZOD NPM 7TO 7U7 C1K H94 K9. NAPCQ 7X8 5PM |
| ID | FETCH-LOGICAL-c4483-a076d4cd9696333c94c0b1c04391f6bd5cbcd00812e66268887c79da5c7eb15f3 |
| IEDL.DBID | WIN |
| ISICitedReferencesCount | 250 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000554953200001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0008-543X 1097-0142 |
| IngestDate | Tue Sep 30 16:52:16 EDT 2025 Thu Oct 02 12:04:23 EDT 2025 Tue Oct 07 07:01:18 EDT 2025 Thu Apr 03 07:01:52 EDT 2025 Sat Nov 29 07:18:07 EST 2025 Tue Nov 18 21:00:39 EST 2025 Wed Aug 20 07:27:06 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 18 |
| Keywords | previously treated CheckMate 025 advanced renal cell carcinoma (aRCC) everolimus immune checkpoint inhibitor nivolumab |
| Language | English |
| License | 2020 American Cancer Society. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4483-a076d4cd9696333c94c0b1c04391f6bd5cbcd00812e66268887c79da5c7eb15f3 |
| Notes | We thank the patients and their families as well as the investigators and participating clinical study teams for making this study possible. We also thank Elmer Berghorn for his contributions to the study; Dako (an Agilent Technologies, Inc, company) for collaborative development of the PD‐L1 IHC 28‐8 pharmDx assay; and Bristol‐Myers Squibb Company (Princeton, New Jersey) and ONO Pharmaceutical Company, Ltd (Osaka, Japan). Professional medical writing and editorial assistance was provided by Jenny Reinhold, PharmD (Parexel), and was funded by Bristol‐Myers Squibb Company. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3 AUTHOR CONTRIBUTIONS Robert J. Motzer: conceptualization, investigation, validation, writing – review and editing. Bernard Escudier: investigation, validation, writing – review and editing. Saby George: investigation, validation, writing – review and editing. Hans J. Hammers: investigation, validation, writing – review and editing. Sandhya Srinivas: investigation, validation, writing – review and editing. Scott S. Tykodi: investigation, validation, writing – review and editing. Jeffrey A. Sosman: investigation, validation, writing – review and editing. Elizabeth R. Plimack, MD: investigation, validation, writing – review and editing. Giuseppe Procopio, MD: investigation, validation, writing – review and editing. David F. McDermott, MD: investigation, validation, writing – review and editing. Daniel Castellano: investigation, validation, writing – review and editing. Toni K. Choueiri: investigation, validation, writing – review and editing. Frede Donskov: investigation, validation, writing – review and editing. Howard Gurney: investigation, validation, writing – review and editing. Stéphane Oudard: investigation, validation, writing – review and editing. Martin Richardet: investigation, validation, writing – review and editing. Katriina Peltola: investigation, validation, writing – review and editing. Ajjai S. Alva: investigation, validation, writing – review and editing. Michael A. Carducci: investigation, validation, writing – review and editing. John Wagstaff: investigation, validation, writing – review and editing. Christine Chevreau: investigation, validation, writing – review and editing. Satoshi Fukasawa: investigation, validation, writing – review and editing. Yoshihiko Tomita: investigation, validation, writing – review and editing. Thomas C. Gauler: investigation, validation, writing – review and editing. Christian K. Kollmannsberger: investigation, validation, writing – review and editing. Fabio A. Schutz: investigation, validation, writing – review and editing. James M. Larkin: investigation, validation, writing – review and editing. David Cella: investigation, validation, writing – review and editing. M. Brent McHenry: conceptualization, data curation, formal analysis, methodology, project administration, resources, software, supervision, validation”.. Shruti Shally Saggi: conceptualization, data curation, formal analysis, methodology, project administration, resources, software, supervision, validation”.. Nizar M. Tannir: conceptualization, investigation, validation, writing – review and editing.. |
| ORCID | 0000-0002-2498-402X 0000-0002-9201-3217 0000-0001-6925-2327 0000-0002-1140-5981 0000-0001-9866-913X |
| OpenAccessLink | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cncr.33033 |
| PMID | 32673417 |
| PQID | 2436891264 |
| PQPubID | 2045183 |
| PageCount | 12 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_8415096 proquest_miscellaneous_2425002722 proquest_journals_2436891264 pubmed_primary_32673417 crossref_citationtrail_10_1002_cncr_33033 crossref_primary_10_1002_cncr_33033 wiley_primary_10_1002_cncr_33033_CNCR33033 |
| PublicationCentury | 2000 |
| PublicationDate | September 15, 2020 |
| PublicationDateYYYYMMDD | 2020-09-15 |
| PublicationDate_xml | – month: 09 year: 2020 text: September 15, 2020 day: 15 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: Atlanta |
| PublicationTitle | Cancer |
| PublicationTitleAlternate | Cancer |
| PublicationYear | 2020 |
| Publisher | Wiley Subscription Services, Inc |
| Publisher_xml | – name: Wiley Subscription Services, Inc |
| References | 2019; 20 2000; 6 2010; 28 1995; 13 1934; 26 2015; 33 2002; 99 2015; 373 1958; 53 2019 2018 2020; 25 2018; 23 2016; 17 2007; 10 1972; 34 2016; 22 (e_1_2_9_2_1) 2019 e_1_2_9_11_1 e_1_2_9_10_1 e_1_2_9_13_1 e_1_2_9_12_1 Fisher RI (e_1_2_9_14_1) 2000; 6 (e_1_2_9_25_1) 2019 e_1_2_9_15_1 e_1_2_9_17_1 e_1_2_9_16_1 e_1_2_9_19_1 e_1_2_9_18_1 e_1_2_9_20_1 e_1_2_9_22_1 e_1_2_9_21_1 e_1_2_9_23_1 e_1_2_9_8_1 (e_1_2_9_24_1) 2019 e_1_2_9_7_1 e_1_2_9_6_1 e_1_2_9_5_1 e_1_2_9_4_1 e_1_2_9_3_1 e_1_2_9_9_1 e_1_2_9_26_1 |
| References_xml | – volume: 10 start-page: 285 year: 2007 end-page: 293 article-title: Development and validation of a scale to measure disease‐related symptoms of kidney cancer publication-title: Value Health – volume: 26 start-page: 404 year: 1934 end-page: 413 article-title: The use of confidence or fiducial limits illustrated in the case of the binomial publication-title: Biometrika – volume: 23 start-page: 540 year: 2018 end-page: 555 article-title: Second‐line treatment landscape for renal cell carcinoma: a comprehensive review publication-title: Oncologist – volume: 33 start-page: 2013 year: 2015 end-page: 2020 article-title: Survival, durable response, and long‐term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab publication-title: J Clin Oncol – volume: 53 start-page: 457 year: 1958 end-page: 481 article-title: Nonparametric estimation from incomplete observations publication-title: J Am Stat Assoc – volume: 13 start-page: 688 year: 1995 end-page: 696 article-title: Results of treatment of 255 patients with metastatic renal cell carcinoma who received high‐dose recombinant interleukin‐2 therapy publication-title: J Clin Oncol – volume: 99 start-page: 12293 year: 2002 end-page: 12297 article-title: Involvement of PD‐L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD‐L1 blockade publication-title: Proc Natl Acad Sci U S A – volume: 17 start-page: 994 year: 2016 end-page: 1003 article-title: Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open‐label, phase 3 trial publication-title: Lancet Oncol – volume: 25 start-page: 252 year: 2020 end-page: 258 article-title: Nivolumab for the treatment of patients with metastatic non–clear cell renal cell carcinoma (nccRCC): a single‐institutional experience and literature meta‐analysis publication-title: Oncologist – volume: 22 start-page: 5461 year: 2016 end-page: 5471 article-title: Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma publication-title: Clin Cancer Res – volume: 34 start-page: 187 year: 1972 end-page: 220 article-title: Regression models and life tables publication-title: J R Stat Soc Series B Stat Methodol – volume: 373 start-page: 1803 year: 2015 end-page: 1813 article-title: Nivolumab versus everolimus in advanced renal‐cell carcinoma publication-title: N Engl J Med – year: 2018 – year: 2019 – volume: 28 start-page: 3167 year: 2010 end-page: 3175 article-title: Phase I study of single‐agent anti–programmed death‐1 (MDX‐1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates publication-title: J Clin Oncol – volume: 20 start-page: 1370 year: 2019 end-page: 1385 article-title: Nivolumab plus ipilimumab versus sunitinib in first‐line treatment for advanced renal cell carcinoma: extended follow‐up of efficacy and safety results from a randomised, controlled, phase 3 trial publication-title: Lancet Oncol – volume: 6 start-page: S55 issue: suppl 1 year: 2000 end-page: S57 article-title: Long‐term survival update for high‐dose recombinant interleukin‐2 in patients with renal cell carcinoma publication-title: Cancer J Sci Am – volume: 33 start-page: 1430 year: 2015 end-page: 1437 article-title: Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial publication-title: J Clin Oncol – volume-title: Bavencio (avelumab) [package insert] year: 2019 ident: e_1_2_9_24_1 – ident: e_1_2_9_15_1 doi: 10.1634/theoncologist.2017-0534 – ident: e_1_2_9_11_1 doi: 10.1093/biomet/26.4.404 – ident: e_1_2_9_13_1 doi: 10.1200/JCO.1995.13.3.688 – ident: e_1_2_9_4_1 doi: 10.1073/pnas.192461099 – ident: e_1_2_9_8_1 doi: 10.1111/j.1524-4733.2007.00183.x – volume-title: Keytruda (pembrolizumab) [package insert] year: 2019 ident: e_1_2_9_25_1 – ident: e_1_2_9_7_1 – volume: 6 start-page: S55 issue: 1 year: 2000 ident: e_1_2_9_14_1 article-title: Long‐term survival update for high‐dose recombinant interleukin‐2 in patients with renal cell carcinoma publication-title: Cancer J Sci Am – ident: e_1_2_9_16_1 doi: 10.1200/JCO.2014.59.0703 – ident: e_1_2_9_19_1 – ident: e_1_2_9_17_1 doi: 10.1158/1078-0432.CCR-15-2839 – ident: e_1_2_9_3_1 doi: 10.1200/JCO.2009.26.7609 – ident: e_1_2_9_9_1 doi: 10.1002/cncr.21979 – ident: e_1_2_9_21_1 – ident: e_1_2_9_10_1 doi: 10.1111/j.2517-6161.1972.tb00899.x – ident: e_1_2_9_12_1 doi: 10.1016/S1470-2045(19)30413-9 – ident: e_1_2_9_6_1 doi: 10.1016/S1470-2045(16)30125-5 – ident: e_1_2_9_18_1 doi: 10.1200/JCO.2014.58.1041 – ident: e_1_2_9_22_1 – ident: e_1_2_9_23_1 – ident: e_1_2_9_26_1 – volume-title: Opdivo (nivolumab) [package insert] year: 2019 ident: e_1_2_9_2_1 – ident: e_1_2_9_5_1 doi: 10.1056/NEJMoa1510665 – ident: e_1_2_9_20_1 doi: 10.1634/theoncologist.2019-0372 |
| SSID | ssj0007253 |
| Score | 2.6924348 |
| Snippet | Background
CheckMate 025 has shown superior efficacy for nivolumab over everolimus in patients with advanced renal cell carcinoma (aRCC) along with improved... The results of the 5‐year follow‐up analysis of the CheckMate 025 trial demonstrate that the clinical benefits are sustained with nivolumab over everolimus in... CheckMate 025 has shown superior efficacy for nivolumab over everolimus in patients with advanced renal cell carcinoma (aRCC) along with improved safety and... BackgroundCheckMate 025 has shown superior efficacy for nivolumab over everolimus in patients with advanced renal cell carcinoma (aRCC) along with improved... CheckMate 025 compared the effects of nivolumab (a novel immunotherapy) with everolimus (an older standard-of-care therapy) for the treatment of advanced... |
| SourceID | pubmedcentral proquest pubmed crossref wiley |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 4156 |
| SubjectTerms | advanced renal cell carcinoma (aRCC) Antiangiogenics Cancer CheckMate 025 Clear cell-type renal cell carcinoma everolimus Fatigue immune checkpoint inhibitor Immune checkpoint inhibitors Immunotherapy Inhibitor drugs Kidney cancer Kidneys Monoclonal antibodies nivolumab Oncology Patients previously treated Pruritus Quality of life Randomization Renal cell carcinoma Safety Safety management Stomatitis Survival Targeted cancer therapy Toxicity |
| Title | Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fcncr.33033 https://www.ncbi.nlm.nih.gov/pubmed/32673417 https://www.proquest.com/docview/2436891264 https://www.proquest.com/docview/2425002722 https://pubmed.ncbi.nlm.nih.gov/PMC8415096 |
| Volume | 126 |
| WOSCitedRecordID | wos000554953200001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVWIB databaseName: Wiley Online Library Free Content customDbUrl: eissn: 1097-0142 dateEnd: 20241209 omitProxy: false ssIdentifier: ssj0007253 issn: 0008-543X databaseCode: WIN dateStart: 19960101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell – providerCode: PRVWIB databaseName: Wiley Online Library Full Collection 2020 customDbUrl: eissn: 1097-0142 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0007253 issn: 0008-543X databaseCode: DRFUL dateStart: 19960101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3bitRAEC3WVcQX75foOrToi7Jxk86lE_FFRgeF3SCLo_MW0p2OE8wkw2Sj4JOf4M_4Q36JVbmtw4ogPqVDVy6kq7pOVbpPATxKHZlwJbSpMy5MN7SUKRPfNgW3Ah2gj9BtKvv9oYiiYLEI3-7A82EvTMcPMSbcyDLa-ZoMPJH1wSlpqCrV5ilG4w5RfdquTeULPryJxmlY8J6C0gpMz3UWIzcpPzi9dNsbnYGYZ1dK_o5gWxc0u_J_L38VLvfQk73odOUa7OjyOlw86n-u34AfUd7OVYlktFajqZnGY1XkK2zmJespWGtGuVs2LB5gG013pR8ATFFhorJaJc_YfE2pBOqtm2K4pqjKjz-_fSdvwDJUwOoLnjVrVmUMcShDt5lWq_yrTvcZVfXCTtRRXeyz9RKdLXPYdKnVpyO8MUMQxdqKIzdhPnv1bvra7Ks6mApDQcdMLOGnrkqJlsdxHBW6ypK2oi26dubL1FNSpYRUuPYx2sIIXSgRpomHGiVtL3NuwW5ZlfoOMF8KbbvcEpqnGJhKmWid2cpHxx-6iGsNeDyMbqx6ynOqvFHEHVkzj2kc4nYcDHg4yq47oo8_Su0NShL3xl7HnFj8QxuhpQEPxm40U_r0SamrhmQQa1pccG7A7U6nxscgghYIJoQBYkvbRgGiAN_uKfNlSwUeIP7CINSAJ622_eXN42k0PW5bd_9F-B5c4pRhoKIZ3h7snmwafR8uqM8neb2ZwDmxCCZw_uXxbH44ae3vFxrDN_Q |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3NjpRAEO7oatSL_z_oqmX04mZxoRto8GYmbnbjDDFmV-dGoGkcIgOTYdHEk4_gy_hCPolVPQzrZI2J8USTLn5CV3V9VXR_xdizXGQpV1LbuuDS9iJH2VkauLbkTqhD9BHapLLfj2Uch9Np9LZfm0N7YVb8EEPCjSzDzNdk4JSQ3jtlDVW1Wr7AcFyI8-yCh0iDKjd8OIyHiVjynoTSCW3fE9OBnZTvnV676Y_OgMyzayV_x7DGCe1f-8_Xv86u9ugTXq3U5QY7p-ub7NKk_79-i_2ISzNdpRnQco2uBY3Hpirn2Cxr6FlYW6D0LazXD8BS013pHwAoqk1UN_P0JRwvKJtAvW1Xra-pmvrjz2_fySFAgTrYfMGzbgFNAQhFAT1n3szLrzrfBSrshZ2oprrahcUM_S0IGM20-jTBGwPiKDBFR26z4_3XR6MDuy_sYCuMBoWdOjLIPZUTM48QQkWecjJX0S5dtwiy3FeZygmscB1gwIVBulQyylMflSpz_ULcYVt1U-t7DIJMatfjjtQ8x9g0y1KtC1cF6PsjD6GtxZ6vhzdRPes5Fd-okhVfM09oHBIzDhZ7OsguVlwff5TaXmtJ0tt7m3Ai8o9cRJcWezJ0o6XSp09r3XQkg3DT4ZJzi91dKdXwGATREvGEtJjcULdBgFjAN3vqcmbYwEOEYBiHWmzHqNtf3jwZxaN3pnX_X4Qfs8sHR5NxMj6M3zxgVzglHKiGhr_Ntk6WnX7ILqrPJ2W7fGTM7xc_tzmK |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3bjpRAEK3orNn44v2CrtpGXzSLC82lwTcz60TjLNlsHDNvhG4ah8gAGRZNfPIT_Bl_yC-ximFYJ2tMjE9Aurh2Vdep6uYUwNPUkQlXQps648J0Q0uZMvFtU3Ar0AH6CN2lsj9MRRQF83l43K_NoX9h1vwQQ8KNLKMbr8nAdZ1mB2esoapUqxcYjjvORdhxqYrMCHYOTyaz6TAUC97TUFqB6bnOfOAn5QdnZ297pHMw8_xqyd9RbOeGJlf_8wWuwZUef7JXa4W5Dhd0eQN2j_oZ9pvwI8q7ASuRjBZstA3TuK2KfIm7ecl6HtaGUQKXbVYQsJWmq9IsAFNUnaislslLNqspn0CtTVtszimq8uPPb9_JJbAMtbD6gkdtzaqMIRhl6DvTapl_1ek-o9Je2IiKqot9Vi_Q4zKHjRdafTrCCzNEUqwrO3ILZpPX78dvzL60g6kwHnTMxBJ-6qqUuHkcx1GhqyxpK_pP1858mXpKqpTgCtc-hlwYpgslwjTxUK2k7WXObRiVVanvAvOl0LbLLaF5itGplInWma189P6hi-DWgGeb7o1Vz3tO5TeKeM3YzGPqh7jrBwOeDLL1mu3jj1J7Gy2Je4tvYk5U_qGN-NKAx0Mz2ip9-qTUVUsyCDgtLjg34M5aqYbbIIwWiCiEAWJL3QYB4gHfbinzRccHHiAIw0jUgOeduv3lyeNxND7p9u79i_Aj2D0-nMTTt9G7-3CZU8aBimh4ezA6XbX6AVxSn0_zZvWwt79fWkw6Mw |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Nivolumab+versus+everolimus+in+patients+with+advanced+renal+cell+carcinoma%3A+Updated+results+with+long-term+follow-up+of+the+randomized%2C+open-label%2C+phase+3+CheckMate+025+trial&rft.jtitle=Cancer&rft.au=Motzer%2C+Robert+J&rft.au=Escudier%2C+Bernard&rft.au=George%2C+Saby&rft.au=Hammers%2C+Hans+J&rft.date=2020-09-15&rft.eissn=1097-0142&rft.volume=126&rft.issue=18&rft.spage=4156&rft_id=info:doi/10.1002%2Fcncr.33033&rft_id=info%3Apmid%2F32673417&rft.externalDocID=32673417 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0008-543X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0008-543X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0008-543X&client=summon |